This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Longley, D. B. Articles by Johnston, P. G. Search for Related Content PubMed PubMed Citation Articles by Longley, D. B. Articles by Johnston, P. G.

The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites

Department of Oncology, Cancer Research Centre, Queen’s University Belfast, Belfast, Northern Ireland

Fas (CD95/Apo-1) is a member of the tumor necrosis factor receptor family. Receptor binding results in activation of caspase 8, leading to activation of proapoptotic downstream molecules. We found that expression of Fas was up-regulated >10-fold in MCF-7 breast and HCT116 and RKO colon cancer cell lines after treatment with IC₆₀ doses of 5-fluorouracil (5-FU) and raltitrexed (RTX). Combined treatment with the agonistic Fas antibody CH-11 and either 5-FU or RTX resulted in a highly synergistic induction of apoptosis in these cell lines. Similar results were obtained for another antifolate, Alimta. Induction of thymidylate synthase expression inhibited Fas induction in response to RTX and Alimta, but not in response to 5-FU. Furthermore, thymidylate synthase induction abrogated the synergy between CH-11 and both antifolates but had no effect on the synergistic interaction between 5-FU and CH-11. Inactivation of p53 in MCF-7 and HCT116 cell lines blocked 5-FU- and antifolate-mediated up-regulation of Fas. Furthermore, Fas was not up-regulated in response to 5-FU or antifolates in the p53-mutant H630 colon cancer cell line. Lack of Fas up-regulation in the p53-null and -mutant lines abolished the synergistic interaction between 5-FU and CH-11. Interestingly, synergy was still observed between the antifolates and CH-11 in the p53-null HCT116 and p53-mutant H630 cell lines, although this was significantly reduced compared with the p53 wild-type cell lines. Our results indicate that Fas is an important mediator of apoptosis in response to both 5-FU and antifolates.

This article has been cited by other articles:

				M. Bagnoli, E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, B. Marcomini, S. Canevari, and D. Mezzanzanica Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment Mol. Cancer Ther., February 1, 2007; 6(2): 762 - 772. [Abstract] [Full Text] [PDF]

				S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer Ann. Onc., December 1, 2006; 17(12): 1810 - 1817. [Abstract] [Full Text] [PDF]

				C. Leonetti, M. Scarsella, G. Zupi, W. Zoli, D. Amadori, L. Medri, F. Fabbri, M. Rosetti, P. Ulivi, L. Cecconetto, et al. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol. Cancer Ther., April 1, 2006; 5(4): 919 - 926. [Abstract] [Full Text] [PDF]

				M Hartel, F F di Mola, F Selvaggi, G Mascetta, M N Wente, K Felix, N A Giese, U Hinz, P Di Sebastiano, M W Buchler, et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management Gut, April 1, 2006; 55(4): 519 - 528. [Abstract] [Full Text] [PDF]

				L. E. Toner, R. Vrhovac, E. A. Smith, J. Gardner, M. Heaney, M. Gonen, J. Teruya-Feldstein, F. Sirotnak, and O. A. O'Connor The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma Clin. Cancer Res., February 1, 2006; 12(3): 924 - 932. [Abstract] [Full Text] [PDF]

				C. J. Allegra and R. W. Childs Cytotoxins and Cancer Immunotherapy: The Dance of the Macabre? J Natl Cancer Inst, October 5, 2005; 97(19): 1396 - 1397. [Full Text] [PDF]

				U. McDermott, D. B. Longley, L. Galligan, W. Allen, T. Wilson, and P. G. Johnston Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer Cancer Res., October 1, 2005; 65(19): 8951 - 8960. [Abstract] [Full Text] [PDF]

				M. A. Morgan, L. A. Parsels, J. D. Parsels, A. K. Mesiwala, J. Maybaum, and T. S. Lawrence Role of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine Cancer Res., August 1, 2005; 65(15): 6835 - 6842. [Abstract] [Full Text] [PDF]

				J. L. Ricker, Z. Chen, X. P. Yang, V. S. Pribluda, G. M. Swartz, and C. Van Waes 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1{alpha}, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., December 15, 2004; 10(24): 8665 - 8673. [Abstract] [Full Text] [PDF]